Guardant Health, Inc. - Common Stock (GH)

Shield cost per test beat its target early while screening guidance moved higher.

Diagnostics company Guardant Health (NASDAQ:GH) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 36.1% year on year to $36...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Guardant Health (NASDAQ:GH) raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based cancer screening test. The company reported revenue of $361 million for the quarter ended Sept. 30,

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 36.1% year on year to $361 million. The c...

Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings this Thursday after the bell. Here’s what to expect. Guardant Health beat analysts...

What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 93.5%, hitting $171.24. This was partly due to its solid qu...

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a...

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

You found a great company, then watched it double before you got round to buying.

Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments,

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

Shield screening volumes more than doubled, with UnitedHealth coverage now active.

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $33...

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses. The company also raised its full-year revenue outlook, citing demand for its Guardant360 and Shield o

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $3...

Diagnostics company Guardant Health (NASDAQ:GH) will be announcing earnings results this Thursday after market close. Here’s what to look for. Guardant Healt...